E-Alert Facebook Twitter Forward to a friend Sign up to BNF eNews
Welcome to the May BNF eNewsletter.

This month's eNews includes information about two new drug monographs, for edoxaban and empagliflozin with metformin. You'll also find:

News of NICE technology appraisals for bortezomib, trastuzumab and other drugs;
New guidance for the identification of drug allergy in adults and children;
A reminder about the Centre for Pharmacy Postgraduate Education (CPPE)'s interactive e-learning programme for BNF 71

Kind regards,
BNF Team
Significant changes More >
News More >
How to purchase BNF More >
Monthly price update reminder More >
Drug Safety Update More >
Feedback on our eNewsletter More >
Significant changes
This month's changes to the clinical content of these publications are described in three parts:

• BNF & BNFC update should be read by all users of the BNF or BNF for Children
• BNF update should be read by all users of the BNF
• BNFC update should be read by all users of the BNF for Children
BNF 67

BNF & BNFC update

Drug allergy: new guidance
The BNF and BNF for Children now include guidance about suspected or confirmed drug allergy in adults and children. The guidance describes the different types of reactions that can be associated with drug allergy, and provides details for the course of action when a drug allergy is suspected for common drug groups such as non-steroidal anti-inflammatory drugs (NSAIDs), beta-lactam antibiotics, and anaesthetics. For further information, see adverse reactions to drugs.

BNF update

NICE technology appraisals
A number of NICE technology appraisals have been added to the BNF this month, including:
Bortezomib for previously untreated mantle cell lymphoma
Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
For a list of all NICE technology appraisals added in this update, see changes.

Edoxaban: new drug monograph
Edoxaban is a direct and reversible inhibitor of activated clotting factor X (factor Xa), which prevents conversion of prothrombin to thrombin. It is licensed for the prophylaxis of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. It is also licensed for the treatment of deep-vein thrombosis and pulmonary embolism, and for prophylaxis when these are recurrent. For further information, see edoxaban.

Metformin with empagliflozin: new drug monograph
Metformin is available in combination with the sodium-glucose co-transporter 2 inhibitor empagliflozin for the treatment of adult patients with type 2 diabetes mellitus not controlled by metformin alone or by metformin in combination with other antidiabetic drugs or insulin. For further information, see empagliflozin with metformin.

Other changes
To review other changes in the BNF, click on changes.

BNFC update

To review changes in BNFC, click on changes.

return to top

Changes to 'Clarifications and Corrections' on
We have retired the 'Clarifications and Corrections' page which was set up for BNF70, and we will return to displaying all future clarifications and corrections on the News page under Clinical news. Keep up to date with clarifications and updates to BNF Publications here.

BNF - market-leading drug information
Online BNF Publications content was viewed more than 6.5 million times in 117 countries in the past year, and over half a million print copies were distributed to health professionals. There were more than 4.5 million uses of the BNF and BNFC app - keeping you informed and up to date with the latest developments.

What's new in BNF 71? CPPE
An interactive PDF e-learning programme outlining the significant changes in BNF 71 is now available from CPPE. This programme will help users to familiarise themselves with new recommendations and the latest information in BNF 71. It consists of 10 case studies, and can be accessed via the CPPE website here.

Print editions: reminder about the use of flags to indicate drug-class monographs
In the print editions of BNF Publications, where there is common information relating to a class of drugs, the shared properties are contained in a drug-class monograph. Drug-class monographs are highlighted by a circled flag symbol beside the title of the drug-class monograph.

Beta-adrenocoptor blockers Atenolol

The corresponding individual drug monographs usually follow the drug-class monograph, and are highlighted by a non-circled flag symbol. For example, the monograph for atenolol will display a flag, indicating that the drug-class monograph for Beta-adrenoceptor blockers (systemic) should be consulted in tandem.

For more information, see How to use BNF publications in print in the preface of the current print publications.

How to purchase BNF
Purchase a print copy Purchase print copies
To order the March 2016 edition, visit the Pharmaceutical Press website.
Purchase a print subscription Purchase a print subscription - and save up to 31%
A print subscription is the best way to ensure access to the latest copy of BNF as soon as it publishes. Preferential pricing is available for bulk subscriptions - please contact
BNF online BNF online
Outside the UK, content is available via a subscription to MedicinesComplete. For more information contact
BNF online BNF eBook
BNF is also available as an eBook. Find out more here.
We offer preferential pricing for bulk orders and for members of various professional associations. So if you are buying on behalf of a CCG, Health Board, NHS Trust or other organisation, contact us here. GPs should contact their CCG direct, who can obtain discount when placing a centralised bulk order.
Monthly price update reminder
Prices of all branded medicinal products in the BNF and BNFC are now updated monthly. Prices of generic preparations of medicinal products are updated every 2-4 months, to coincide with print editions of BNF and BNF for Children. The BNF team keeps price information up to date using data sourced from the NHS dictionary of medicines and devices (dm+d).

return to top

Drug Safety Update
Drug Safety UpdateDrug Safety Update is a monthly newsletter from the MHRA and Commission on Human Medicine. Please follow this link to review this month's Drug Safety Update.

return to top

Feedback on our eNewsletter
Please let us know if there are any issues that you would like us to address in eNewsletters. We welcome your feedback. If you have any comments or suggestions please let us know at

Subscribe to this eNewsletter here.

return to top

Related Products
MedicinesComplete BNF on FormularyComplete Pharmaceutical Press
BNF for Children